Breast Cancer

Breast cancer is a malignant tumor that occurs in the epithelial tissue of the breast. Its incidence ranks the first among female malignant tumors. 99% of breast cancer occurs in women, and it has become a common tumor that threatens women's physical and mental health. The breast is not an important organ for maintaining human life and activities, so breast cancer in situ is not fatal. However, because breast cancer cells have lost the characteristics of normal cells, uncontrolled proliferation of breast cells can spread throughout the body with blood or lymph, forming metastases and endangering life. The cause of breast cancer is not clear and there may be a genetic risk.

Diagnosis of Breast Cancer

The following tests can be used to diagnose breast cancer:

Imaging diagnosis. Including breast mammography--widely used in breast cancer screening, breast ultrasound--to determine the nature of the lump, for the differential diagnosis of breast cancer, breast MRI--for breast cancer staging assessment.

Tissue biopsy. For patients with suspected breast cancer, if the imaging diagnosis is not clear, the tumor can be removed together with the surrounding breast tissue for histopathological examination.

Tumor marker examination. Common examination indicators include serum cancer antigen 15-3 (CA15-3), serum (CEA), serum antigen 125 (CA125), etc., which provide supplementary evidence for the diagnosis of breast cancer, and monitor postoperative recurrence and metastasis.

Immunohistochemical examination. Common examination indicators include Ki-67, HER-2, ER, PR, etc., which are used to diagnose the molecular type of breast cancer and provide a basis for later treatment. Positive ER and PR indicate hormone-dependent breast cancer, while positive Ki-67 and HER-2 indicate that the tumor is highly invasive and prone to recurrence and metastasis.

Advantages of Our Products

Creative Biogene's breast cancer diagnostic products are mainly targeted at tumor markers and immunohistochemistry. They can detect CA125, ER, PR, HER-2 and other indicators. Combined with risk scores, age and lymph node status, comprehensively assess the risk of recurrence and the benefit of chemotherapy, and then guide clinical treatment. The analysis mode of the product is mainly molecular diagnosis, Immunohistology, etc., which has the advantages of fast, efficient and accurate.

Creative Biogene focuses on the field of diagnostic reagents for breast cancer. We promise to provide you with the best diagnostic products. You can choose us with confidence.

Please contact us for more details.

Reference

1. Bozica M, et al. (2018). "Immunohistochemical Analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR Antigen Expression in Medullary Breast Cancer." Tumori Journal. 94.6:838-844.